Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.

Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, Kawasaki D, Zen K, Urasawa K, Shintani Y, Miyamoto A, Hirano K, Miyashita Y, Tsuchiya T, Shinozaki N, Nakamura M, Isshiki T, Hamasaki T, Nanto S; STOP-IC investigators..

Circulation. 2013 Jun 11;127(23):2307-15. doi: 10.1161/CIRCULATIONAHA.112.000711.

2.

Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial.

Park SH, Rha SW, Choi CU, Kim EJ, Oh DJ, Cho YH, Choi WG, Lee SJ, Kim YH, Choi SH, Kim WH, Kim KC, Cho JH, Kim JH, Kim SM, Bae JH, Bong JM, Kang WY, Baek JY, Seo JB, Chung WY, Park MW, Her SH, Suh J, Kim MW, Kim YJ, Choi HJ, Soh JW; SENS-FP Investigators..

Trials. 2014 Sep 10;15:355. doi: 10.1186/1745-6215-15-355.

3.

Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients.

Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Tanaka M, Kamoi D, Kawamura Y, Yamada S, Hayashi M, Yasuda Y, Yuzawa Y, Maruyama S, Matsuo S, Matsubara T, Murohara T.

Clin Ther. 2010 Jan;32(1):24-33. doi: 10.1016/j.clinthera.2010.01.007.

PMID:
20171408
4.

Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions.

Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S.

J Vasc Surg. 2008 Jul;48(1):144-9. doi: 10.1016/j.jvs.2008.02.062.

5.

Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.

Soga Y, Iida O, Hirano K, Suzuki K, Yokoi H, Nobuyoshi M.

Catheter Cardiovasc Interv. 2012 Mar 1;79(4):541-8. doi: 10.1002/ccd.23304.

PMID:
21805619
6.

Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis).

Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, Mena-Hurtado C, Beasley R, Soukas P, Colon-Hernandez PJ, Stark MA, Walker C; EXCITE ISR Investigators..

JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):92-101. doi: 10.1016/j.jcin.2014.09.009.

7.

Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.

Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y, Nobuyoshi M.

J Am Coll Cardiol. 2009 Jan 6;53(1):48-53. doi: 10.1016/j.jacc.2008.09.020.

8.

Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial.

Rastan A, Krankenberg H, Baumgartner I, Blessing E, Müller-Hülsbeck S, Pilger E, Scheinert D, Lammer J, Gißler M, Noory E, Neumann FJ, Zeller T.

Circulation. 2013 Jun 25;127(25):2535-41. doi: 10.1161/CIRCULATIONAHA.113.001849.

9.

A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.

Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Park SJ, Lee JH, Choi SW, Seong IW, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Choi YJ, Kim HS, Lee BK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Park WJ; DECLARE-LONG II Study Investigators..

J Am Coll Cardiol. 2011 Mar 15;57(11):1264-70. doi: 10.1016/j.jacc.2010.10.035.

10.

Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.

Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, Izumi M, Otsuji S, Tateyama H, Sakurai M, Awata N.

Circulation. 1999 Jul 6;100(1):21-6.

11.

PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.

Lichtenberg M, Kolks O, Hailer B, Stahlhoff WF, Tiefenbacher C, Nolte-Ernsting C, Arjumand J, Wittenberg G.

J Endovasc Ther. 2014 Jun;21(3):373-80. doi: 10.1583/13-4637R.1.

PMID:
24915584
12.

Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial.

Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR; RESILIENT Investigators..

Circ Cardiovasc Interv. 2010 Jun 1;3(3):267-76. doi: 10.1161/CIRCINTERVENTIONS.109.903468.

13.

Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center.

Shammas NW, Shammas GA, Helou TJ, Voelliger CM, Mrad L, Jerin M.

Cardiovasc Revasc Med. 2012 Jul-Aug;13(4):224-7. doi: 10.1016/j.carrev.2012.03.004.

PMID:
22575073
14.
15.

Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.

Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, Shintani Y, Suematsu N, Yamaoka T, Nanto S, Uematsu M.

J Endovasc Ther. 2014 Aug;21(4):485-92. doi: 10.1583/14-4721R.1.

PMID:
25101575
16.

Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.

Mori S, Hirano K, Nakano M, Muramatsu T, Tsukahara R, Ito Y, Ishimori H.

J Endovasc Ther. 2015 Jun;22(3):341-9. doi: 10.1177/1526602815580308.

PMID:
25862363
17.

Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia.

Soga Y, Iida O, Kawasaki D, Hirano K, Yamaoka T, Suzuki K.

Eur J Vasc Endovasc Surg. 2012 Dec;44(6):577-81. doi: 10.1016/j.ejvs.2012.09.020.

18.

Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.

Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Machan LS, Snyder SA, O'Leary EE, Ragheb AO, Zeller T; Zilver PTX Investigators..

Circulation. 2016 Apr 12;133(15):1472-83; discussion 1483. doi: 10.1161/CIRCULATIONAHA.115.016900.

19.

Effects of cilostazol on angiographic restenosis after coronary stent placement.

Park SW, Lee CW, Kim HS, Lee NH, Nah DY, Hong MK, Kim JJ, Park SJ.

Am J Cardiol. 2000 Sep 1;86(5):499-503.

PMID:
11009265
20.

The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.

Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K.

JACC Cardiovasc Interv. 2014 Jan;7(1):10-9. doi: 10.1016/j.jcin.2013.05.022.

Items per page

Supplemental Content

Support Center